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Abstract
 
Dendritic cells (DCs), unique antigen-presenting cells (APCs) with potent T cell stimulatory ca-
pacity, direct the activation and differentiation of T cells by providing costimulatory signals. As
such, they are critical regulators of both natural and vaccine-induced immune responses. A new
B7 family member, B7-DC, whose expression is highly restricted to DCs, was identified among
a library of genes differentially expressed between DCs and activated macrophages. B7-DC fails
to bind the B7.1/2 receptors CD28 and cytotoxic T lymphocyte–associated antigen (CTLA)-4,
but does bind PD-1, a receptor for B7-H1/PD-L1. B7-DC costimulates T cell proliferation
more efficiently than B7.1 and induces a distinct pattern of lymphokine secretion. In particular,
 
B7-DC strongly costimulates interferon 
 
g
 
 but not interleukin (IL)-4 or IL-10 production from
isolated naive T cells. These properties of B7-DC may account for some of the unique activity
of DCs, such as their ability to initiate potent T helper cell type 1 responses.
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g
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Introduction
 
The qualitative and quantitative nature of an immune re-
sponse depends on the type of APC that processes and pre-
sents antigen to T cells. Critical determinants of T cell acti-
vation include the density of peptide-MHC ligand available
for TCR engagement as well as the provision of soluble
and membrane-bound costimulatory signals. Among the
different types of APCs, dendritic cells (DCs)
 
1
 
 are the cen-
tral initiator of antigen-specific T cell responses. Early DCs
have specialized antigen uptake and processing machinery,
whereas mature DCs efficiently present antigen to and acti-
vate T cells. Functionally, mature DCs are 
 
.
 
100 times
more potent than macrophages in activating naive T cell in
vitro (1, 2).
T cell–dependent immune responses initiated by DCs
depend on their expression of specific costimulatory signals.
Among the most important costimulatory signals are those
delivered by the B7 family, which is currently composed of
four members with demonstrated immunologic activity.
Two of the members, B7.1 and B7.2, bind both CD28 and
CTL-associated antigen (CTLA)-4 on T cells. CD28 deliv-
ers a positive costimulatory signal (3–5), enhancing the pro-
duction of certain lymphokines such as IL-2 via transcrip-
tional (6) and posttranscriptional mechanisms (7). CTLA-4,
which is expressed a few days after T cell activation, delivers
a counterregulatory negative signal that antagonizes CD28
signals and thereby limits the magnitude and duration of T
cell activation (8, 9). B7.1 and B7.2 are expressed by all
 
bone marrow–derived APCs including B cells, macro-
phages, and DCs, although at different ratios and with dif-
ferent kinetics. Despite many reports suggesting different
functions of B7.1 and B7.2 in Th1/Th2 differentiation, an-
tibody production, and CTL generation (10–13), their dis-
tinct immunologic roles remain to be clarified (14–16).
 
Two additional B7 family members, B7-H1/PD-L1
and B7h/B7RP-1, have been identified recently (17–20).
B7-H1/PD-L1 and B7h/B7RP-1 bind the PD-1 and in-
ducible costimulator (ICOS) receptors, respectively, both
of which are induced upon T cell activation (18, 21). Ex-
pression of all the currently known B7 family members is
broadly distributed on multiple hematopoietic and nonhe-
matopoietic tissues, raising interesting questions as to their
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Abbreviations used in this paper:
 
 aa, amino acid(s); BAC, bacterial artifi-
cial chromosome; CTLA, CTL-associated antigen; DC, dendritic cell;
HA, hemagglutinin; RACE, rapid amplification of cDNA ends; RT, re-
verse transcription. 
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relative role in immune response regulation. In vivo
experiments in transgenic and knockout mice have
confirmed a role for B7h/B7RP-1 in effector responses,
particularly involving antibody production (21–24). Al-
though expression of the currently described B7 family
molecules is clearly important in mediating T cell activa-
tion, their ubiquitous expression on multiple APC types
suggests that other molecules contribute to the extraordi-
nary stimulatory capacity of DCs.
In an effort to understand more about genes involved in
DC function, we screened a subtractive cDNA library be-
tween DCs and activated macrophages. We have isolated a
new member of the B7 family that appears to be expressed
primarily in DCs in mouse and human. Our initial func-
tional studies indicate that B7-DC is more active than B7-1
in stimulating IFN-
 
g
 
 production by T cells.
 
Materials and Methods
 
Cell Preparation and Culture.
 
6–12-wk-old female BALB/c
mice were purchased from National Cancer Institute and used for
DC and macrophage preparation. Bone marrow–derived DCs
were cultured in RPMI 1640 (GIBCO BRL) supplemented with
5% FCS (Hyclone), penicillin/streptomycin (JRH Biosciences),
gentamycin (Sigma-Aldrich), nonessential amino acids (aa; RH
Biosciences), 
 
l
 
-glutamate (JRH Biosciences), sodium pyruvate
(Sigma-Aldrich), 2-mercaptoethanol (Sigma-Aldrich), and 1,000
U/ml recombinant murine GM-CSF (Immunex), as described
previously (25). Day 8 bone marrow–derived DCs were stained
with monoclonal antibodies by conventional methods. Mono-
clonal antibody against MHC class II, 14-4-4s, was purified from
hybridoma supernatant. Dr. W. Baldwin (Johns Hopkins Univer-
sity) supplied CTLA-4-Ig fusion molecule. Antibodies for MHC
class I (28-14-8), F4/80 (C1.A3-1), B7.1 (1G10), B7.2 (GL1),
Fc
 
g
 
 RII/III (2.4G2), and Mac-1 (M1/70) were purchased from
BD PharMingen. For tester cDNA preparation, day 8 cells were
purified by cell sorter using 14-4-4s and CTLA-4-Ig at the Johns
Hopkins University Oncology Center. The purity of MHC class
II
 
hi
 
 and B7
 
hi 
 
population after sorting was 93–98%. Bone marrow–
derived macrophages were cultured with RPMI 1640 supple-
mented with 10% FCS, penicillin/streptomycin, nonessential aa,
sodium pyruvate, 
 
l-
 
glutamine, 2-mercaptoethanol, and 250 U/ml
recombinant murine M-CSF, and they were treated with 500 U/ml
IFN-
 
g
 
 (BD PharMingen) and 5 
 
m
 
g/ml LPS (Sigma-Aldrich), as
described previously (26). After stimulation, cell surface expres-
sion of MHC class II and B7 were confirmed using flow cytomet-
ric analysis on day 10 of culture. Macrophage cell lines WEHI-3,
RAW264.7, J774.A.1, and PU5-1.8 were provided by Dr. J. Far-
ber (National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Bethesda, MD). They were cultured with
American Type Culture Collection recommended medium.
 
cDNA Subtractive Hybridization.
 
Total RNA from sorted DCs
and activated macrophages was extracted with TRIzol (GIBCO
BRL). Messenger RNA was purified by Oligotex mRNA purifi-
cation kit (QIAGEN). We used the PCR-based SMART cDNA
synthesis system (CLONTECH Laboratories, Inc.) to amplify
cDNA followed by the PCR-based subtraction system PCR Se-
lect (CLONTECH Laboratories, Inc.). Subtraction was per-
formed following the manufacturer’s protocol. Plasmid dot blot
was then performed to confirm that the cDNA cloned is DC spe-
cific. Alkaline-denatured miniprep DNAs were spotted on Hy-
 
bond N
 
1
 
 membrane (Amersham Pharmacia Biotech) and hybrid-
ized with SMART cDNA probe derived from sorted DCs or
activated macrophages. These cDNA probes were 
 
32
 
P-labeled us-
ing random primer labeling method (Prime-It II; Stratagene). Hy-
bridizations and washing were done as described previously (27).
 
cDNA Library Construction and Screening: Cloning of B7-DC.
 
Bone marrow–derived DCs were harvested on day 8 without
sorting. About 20 to 40% of these cells expressed high MHC class
II and B7. Total RNA extraction followed by poly A RNA puri-
fication was done as described above. For oligo dT primed DC
library construction, we used Lambda ZAP Express cDNA syn-
thesis system (Stratagene). The PCR DNA fragment of B7-DC
was probed and used for screening. Membrane transfer, denatur-
ation, and renaturation were performed using Stratagene’s proto-
col. Positive clones were isolated and second screening was per-
formed. After second screening, plasmids were excised by in vivo
excision and tested by dot blotting and sequencing. The BLAST
program was used to do homology search of the nucleotide se-
quence against GenBank (National Center for Biotechnology In-
formation) for similarity to previously reported genes. The full-
length B7-DC cDNA clone was pulled out from the DC cDNA
library. 5
 
9
 
 rapid amplification of cDNA ends (RACE) was per-
formed using SMART RACE cDNA amplification kit (CLON-
TECH Laboratories, Inc.). 5
 
9
 
-RACE products were cloned into
pCR2.1 vector and sequenced. Two more full-length B7-DC
clones were obtained by reverse transcription (RT)-PCR and
their sequences were compared to avoid sequence error.
For cloning of the human B7-DC, human DCs were obtained
from normal peripheral blood mononuclear cells by culture in
GM-CSF plus IL-4 as described previously (28). A BLAST search
identified an overlapping expressed sequence tag (EST) clone,
under GenBank/EMBL/DDBJ accession no. AK001879, with
homology to mouse B7-DC. 5
 
9
 
 RACE was performed as de-
scribed above. We sequenced a 5
 
9
 
-RACE PCR fragment and
designed a primer corresponding to 5
 
9
 
-UTR of human B7-DC.
The following primers in the 5
 
9
 
-UTR and 3
 
9
 
-UTR of B7-DC
was used to amplify full-length human B7-DC: 5
 
9
 
-GGAGC-
TACTGCATGTTGATTGTTTTG-3
 
9
 
 and 5
 
9
 
-TGCAAACT-
GAGGCACTGAAAAGTC-3
 
9
 
. The full-length cDNA se-
quences of the human and murine B7-DC cDNAs are available
from GenBank/EMBL/DDBJ under accession nos. AF329193
and AF142780.
 
Bacterial Artificial Chromosome (129SVJ) Library Screening/Ge-
nomic Cloning and Mapping.
 
Bacterial artificial chromosome
(BAC) library screening followed manufacturer’s protocol (Ge-
nome Systems, Inc.). Primers used: 5
 
9
 
-TTGTTGTCTCCT-
TCTGTCTCCCAAC-3
 
9
 
 and 5
 
9
 
-ACAGTTGCTCCTTGTAT-
CAGGTTC-3
 
9
 
.
BAC library screening yielded three positive clones. Chromo-
some location mapping was done by fluorescence in situ hybrid-
ization (Genome Systems, Inc.). A total of 80 metaphase cells
were analyzed, with 79 exhibiting specific labeling. The human
B7-DC mapping was done using available bioinformatic tools,
National Center for Biotechnology Information’s BLAST pro-
gram, and the International RH Mapping Consortium. The hB7-
DC sequence was searched in GenBank/EMBL/DDBJ and was
found to map to two BAC clones RP11-574F11 (AL162253) and
Rp11-635N21 (AL354744) localizing on chromosome 9.
 
Hybridization Analysis.
 
RNA extraction and SMART cDNA
synthesis for cell lines, sorted DCs, and activated macrophages
were performed as described above. SMART PCR cDNAs were
purified by PCR purification kit (QIAGEN). 0.5 
 
m
 
g/lane puri-
fied DNAs were run on a 1% agarose gel and transferred on a 
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Nytran nylon membrane (Schleicher & Schuell). To make radio-
active probes, subtracted library-derived plasmid DNAs were am-
plified as templates. DNA was amplified by PCR using primer
sets just adjacent to the cloning site of plasmid DNA and used pu-
rified PCR DNA of each of the clones for hybridization probes.
The nucleotide sequences of these primers are as follows: 5
 
9
 
-
GTAACGGCCGCCAGTGTGCTG-3
 
9
 
 and 5
 
9
 
-CGCCAGT-
GTGATGGATATCTGCA-3
 
9
 
. Hybridization analysis of total
RNA of human DCs and control placenta was also performed.
The probes used and RNA preparation was described above. Ra-
diolabeling of probes, hybridization, washing, and autoradiogra-
phy were done as described above.
 
CD28-Ig, CTLA-4-Ig, and PD-1-Ig Binding Assay.
 
293T
cells were transfected with B7.1-pCAGGS or B7-DC-pCAGGS
using LipofectAMINE 2000 (GIBCO BRL). After 24 h, cells
were resuspended in standard FACS
 
®
 
 buffer and spun at 1,000
rpm for 5 min at 4
 
8
 
C, stained, and analyzed on a FACScan™
(Becton Dickinson). Recombinant CD28-Ig, CTLA-4-Ig, and
PD-L1-Ig chimera were used at 2 
 
m
 
g/ml. Goat F(ab
 
9
 
)
 
2
 
 anti–
human IgG-PE was used at 1:20 dilution (Southern Biotechnol-
ogy Associates, Inc.).
 
B7-DC-Ig Dimer Synthesis.
 
The B7-DC-Ig construct was
made by fusing the sequence encoding the NH
 
2
 
-terminal aa of
B7-DC without the transmembrane domain in-frame to the se-
quence encoding the COOH-terminal aa of the human IgG1 Fc
in the pIg-Tail Plus vector (R&D Systems). COS-7 cells were
transiently transfected with pIg/B7-DC using LipofectAMINE
2000 (GIBCO BRL) or GINE JAMMER (Stratagene). The B7-
DC-Ig fusion protein was purified from the serum-free superna-
tants using the saturated ammonium sulfate precipitation. SDS-
PAGE and silver staining demonstrated a purity 
 
.
 
90%.
 
T Cell Proliferation and Cytokine Assays.
 
For costimulation as-
says with anti-CD3, 96-well flat-bottommed plates (Immulon4;
Dynex) were precoated with anti-CD3 antibodies (2C11; BD
PharMingen) and B7.1-Ig (R&D Systems), B7-DC-Ig, or isotype
control (Sigma-Aldrich) at 100 ng/ml were diluted in 1
 
3
 
 PBS
(GIBCO BRL), pH 7.4, for 2 h at 37
 
8
 
C. The plates were then
washed three times with 1
 
3 
 
PBS and blocked with RPMI 1640
supplemented with 10% FCS for one-half hour before adding T
cells. T cells from spleens and lymph nodes were purified using
dynabeads M-280 (Dynex) with the indirect method using an an-
tibody cocktail composed of anti-IE
 
d
 
 and B220/CD45RO or
CD8
 
a
 
 (BD PharMingen). For proliferation and cytokine secre-
tion assays, cells were plated at 2 
 
3 
 
10
 
5
 
 cells/well.
For costimulation assays using the RENCA system to present
hemagglutinin (HA) antigen, RENCA MHC class II expression
was induced with IFN-
 
g 
 
(75 U/ml) for 72 h. They were then ir-
radiated (13,200 rad) and plated at 2 
 
3
 
 10
 
4
 
 cells/well (96-well
flat-bottomed plates). HA110–120 peptide was then added at 2.5
 
m
 
g/well and various concentrations of the Ig-fusion molecules
were added. Transgenic I-E
 
d
 
 plus HA-specific T cells (gift of H.
von Boehmer, Harvard University, Cambridge, MA) were iso-
lated as described above and plated at 4 
 
3 
 
10
 
5
 
 cells/well.
For analysis by cytokine ELISA, cultures were set up as de-
scribed above and supernatants were harvested at the indicated
times. IL-2, IL-10, IFN-
 
g 
 
(Endogen), and IL-4 (R&D Systems)
concentrations were determined using commercially available
ELISA kits.
 
Results
 
Identification and Characterization of B7-DC.
 
B7-DC
was isolated from a subtracted library between DCs and ac-
tivated macrophages. The two populations used for cDNA
subtraction were bone marrow–derived GM-CSF–cultured
DCs as the “tester” population and IFN-
 
g
 
 plus LPS-acti-
vated adherent bone marrow–derived M-CSF macrophages
as the “driver” population. Day 8 MHC class II
 
hi
 
B7
 
hi
 
 “ma-
ture” DCs were sorted to 
 
.
 
93% purity as the source of
tester cDNA. DCs were characterized by flow cytometry as
having 
 
z
 
50-fold higher MHC class II levels than macro-
phages. Both populations expressed B7.1 and B7.2, al-
though B7.2 levels were significantly higher in the DCs.
F4/80 and CD16 were expressed at higher levels on the
macrophage population. Functional comparison of the two
populations demonstrated that the DC population was
 
z
 
100-fold more potent than the macrophage population
in stimulating an allo-MLR (data not shown).
After RNA extraction from both populations, we used a
PCR-based cDNA synthesis system followed by the PCR-
based subtraction procedure, PCR Select. One of the dif-
ferentially expressed clones encoded a novel Ig supergene
family member, which we name B7-DC. The murine B7-
DC cDNA is 
 
z
 
1.7 kb in length encoding a 247-aa precur-
sor protein with a 23-aa NH
 
2
 
-terminal signal peptide and a
predicted molecular weight of 
 
z
 
25 kD (Fig. 1 a). The pu-
tative leader sequence and transmembrane domain were
identified using the SOSUI program (29). Two charged aa
are found within the 23-aa transmembrane domain of
mB7-DC, suggesting a possible binding partner. At the aa
level, murine B7-DC is 70% identical to the human B7-
DC, indicating that they are orthologues (Fig. 1 a). The
hB7-DC differs slightly from the murine B7-DC in that it
has a longer cytoplasmic tail.
Through a homology search, we found that B7-DC has
significant homology to B7-H1/PD-L1 (34% identity, 48%
similarity; Fig. 1 b), to a lesser extent butyrophilin (30%
identity, 45% similarity), and 
 
,
 
20% identity to B7.1 and
B7.2. Even though no immunologic function has yet been
demonstrated for butyrophilin, phylogenetic studies indi-
cate that it is likely related to the B7 family through exon
shuffling (30, 31). They each possess the canonical IgV-IgC
structure and a transmembrane domain. In contrast to the
other B7 family members, murine B7-DC has an ex-
tremely short cytoplasmic tail (4 aa).
To determine the genomic structure of mB7-DC, we
isolated a genomic clone by screening a pooled BAC li-
brary using probes from the 5
 
9
 
 and 3
 
9
 
 UTRs. Chromo-
some location mapping using the BAC clones showed that
mB7-DC is located between the regions of chromosome
19C2 and 19C3, which corresponds to a region of human
chromosome 9, where hB7-H1/PD-L1 has been mapped
(data not shown). hB7-DC has been found to be located
on two chromosome 9 BAC clones. In addition, both
hB7-DC and hB7-H1/PD-L1 were found to be located on
a single chromosome 9 BAC clone with an insertion size of
 
z
 
164 kb (Fig. 1 c). The genomic proximity of B7-DC and
B7-H1/PD-L1 is reminiscent of the B7.1/B7.2 pair, which
map to within 1 megabase of each other.
 
B7-DC Is Selectively Expressed in DCs.
 
To determine
the expression pattern of B7-DC, virtual Northern blot 
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was performed using RNA extracted from multiple mac-
rophage cell lines, macrophage cultures, and DCs derived
from both bone marrow and spleen. Although strong hy-
bridization was detected using a B7-DC probe in immature
(day 4 and 6) and mature (day 8 and sorted MHC II
 
hi
 
B7
 
hi
 
)
bone marrow–derived DCs and splenic DCs, no signal was
detected in any of four macrophage cell lines, activated
bone marrow macrophages, or peritoneal macrophages
(Fig. 2 a). We were also able to detect strong expression of
hB7-DC in human DCs grown from peripheral blood
mononuclear cells with GM-CSF plus IL-4 (Fig. 2 b).
 
B7-DC Does Not Bind to CD28 or CTLA-4 but Does
Bind to PD-1.
 
Although B7-DC has structural and se-
quence homology to the B7 family, it does not contain the
putative CD28/CTLA-4 binding sequence, SQDXXX-
ELY or XXXYXXRT (32). To directly assess binding, we
analyzed the ability of dimeric CD28-Ig, CTLA-4-Ig to
stain 293T cells transfected with either B7-DC or B7.1.
Whereas strong binding was observed with B7.1 transfec-
tants, there was no binding to B7-DC transfectants (Fig. 3).
Based on the homology and genomic proximity between
B7-DC and B7-H1/PD-L1, we also tested PD-1 as a can-
didate binding partner for B7-DC. Indeed, PD-1-Ig bound
to B7-DC transfectants but not to B7.1 transfectants. The
binding of PD-1-Ig to B7-DC transfectants is lower than
the binding of CTLA-4-Ig and CD28-Ig to B7.1 transfec-
tants, although it is totally specific. Further confirmation of
the binding of PD-1 to B7-DC was obtained from positive
staining of stable B7-DC-GFP transfectants with PD-1-Ig
(data not shown). These results suggest that PD-1 is indeed
a receptor for B7-DC.
 
B7-DC Functions As a Costimulatory Molecule for T
Cells.
 
To determine whether B7-DC possesses costimula-
tory activity, we produced a soluble B7-DC-Ig fusion pro-
tein which could be added to T cell stimulation assays. We
first measured the proliferative response to increasing
Figure 1. Aa sequence of B7-DC and comparison with
other B7 family members. (a) Aa sequence comparison of
murine B7-DC to human B7-DC. The mB7-DC putative
leader and transmembrane domain are underlined. The
alignment was done using Clustawl-Gonnet Pam250 ma-
trix. The red lettering shows identical aa and the blue let-
tering shows conservative substitutions. The asterisks indi-
cate cysteine residues that may be important in the
formation of disulfide bonds inside the IgV or IgC do-
mains. (b) Aa sequence comparison of mB7-DC to mB7-H1/ PD-L1. (c) Both hB7-DC and B7-H1/PD-L1 are localized on human chromosome
9p24 and map to within 150 kb of each other on BAC clone RPCI-11.2. hB7-DC is centromeric to B7-H1.
Figure 2. B7-DC is differentially expressed between DCs
and macrophages. (a) Distribution of mB7-DC mRNA in mu-
rine bone marrow DCs, splenic DCs, macrophages (Mf), and
macrophage lines was assessed by hybridization analysis using
0.5 mg/lane purified cDNA generated by SMART cDNA syn-
thesis and run on a 1% agarose gel. G3PDH is used as control.
J774A1, RAW 264.7, Pu5-1.8, and WEHI are macrophage
cell lines. act., activated; BM, bone marrow. (b) hB7-DC is ex-
pressed in human DCs. Lane 1 shows human placenta and lane
2 shows human DCs cultured with GM-CSF plus IL-4. Oligos
from the 59 and 39 UTR of human B7-DC were used to make
PCR DNA probe for virtual Northern analysis of total RNA
of human DCs. b-actin was used as control to ensure the qual-
ity of mRNA. 
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amounts of plate-bound anti-CD3 in the presence of B7-
DC-Ig, B7.1-Ig, or an isotype control. Fig. 4 a shows that,
in the presence of suboptimal amounts of anti-CD3, B7-
DC costimulates a T cell proliferative response to a greater
level than B7.1. Furthermore, B7-DC costimulates prolif-
erative responses among CD4 cells to a much greater ex-
tent than among CD8 cells (Fig. 4 b). B7-DC fails to stim-
ulate T cells in the absence of a TCR-dependent stimulus,
indicating that it provides a true costimulatory signal.
 
Patterns of Lymphokine Production Costimulated by
B7-DC.
 
The best characterized T cell costimulatory ac-
tivity of B7 family molecules relates to lymphokine pro-
duction, one of the most important mediators of T cell
function. We therefore analyzed production of a panel of
lymphokines by T cells stimulated with anti-CD3 or
MHC-peptide costimulated with B7-DC-Ig, B7.1-Ig, or
an isotype control. For experiments in which signal 1 is
MHC-peptide, RENCA cells (which do not express any
endogenous B7.1, B7.2, or B7-DC by RT-PCR analysis)
were treated with IFN-
 
g
 
 to induce MHC class II expres-
sion and loaded with the I-E
 
d
 
–restricted HA 110–120 pep-
tide (FERFEIFPKE; reference 33). Purified splenic T cells
from an I-E
 
d
 
 plus HA 110–120-specific TCR transgenic
mouse line were added and the proliferative response was
measured in the presence of either B7-DC-Ig, B7.1-Ig, or
an isotype control.
Fig. 4, c and d, demonstrate that patterns of lymphokine
costimulation are fairly consistent whether anti-CD3 or
Figure 3. B7-DC binds PD-1 but not CD28 or
CTLA-4. 293T cells were transiently transfected with
pCAGGS-B7.1 or pCAGGS-B7-DC. Transfectants were
stained with PD-1-Ig, CD28-Ig, and CTLA-4-Ig fusion
molecules followed by PE-labeled secondary antibody.
Staining of pCAGGS (empty vector) transfectants was
negative (data not shown).
Figure 4. Costimulation of T cells by B7-DC. (a)
Purified T cells (CD4 plus CD8) were cultured in the
presence of increasing concentrations of precoated an-
tibody against CD3 (monoclonal antibody 2C11) and a
constant amount of immobilized B7.1-Ig (r), B7-DC-
Ig (d), or isotype control (m). The concentration of
the Ig-fusion molecules used was 0.1 mg/ml. Data de-
pict one representative experiment of three. (b) Puri-
fied CD8 T cells were cultured in the presence of in-
creasing concentrations of precoated antibody against
CD3 and a constant amount of immobilized B7.1-Ig
(r), B7-DC-Ig (d), or isotype control (m) as in panel
a. Data depict one representative experiment of two.
Cells were incubated for 72 h and labeled with
[3H]thymidine. (c) For analysis of cytokine secretion,
purified T cells were cultured in the presence of pre-
coated anti-CD3 (0.12 mg/ml) and 0.1 mg/ml of im-
mobilized B7.1-Ig (r), B7-DC-Ig (d), or isotype con-
trol (m) as in panel a. Supernatants were collected after
24 and 48 h culture and assayed for the indicated lym-
phokines using ELISA. Data depict one representative
experiment of three. (d) IFN-g–treated RENCA cells
expressing MHC class II were loaded with 12.5 mg/ml
HA110–120 peptide and incubated with purified HA
plus I-Ed–specific transgenic T cells together with 2
mg/ml of soluble B7.1-Ig (r), B7-DC-Ig (d), or iso-
type control (m). Data depict one representative exper-
iment of two. Supernatants were collected after 24 and
48 h culture and assayed for the indicated lymphokines
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MHC-peptide complex is used as “signal 1”. Significantly,
although both costimulate similar levels of IL-2, B7-DC
costimulates much greater levels of IFN-g production than
B7.1. In contrast, B7-DC fails to costimulate IL-4 or IL-10
production. These findings implicate B7-DC as a DC sig-
nal to drive Th1 responses.
Discussion
We have characterized here a new B7 family member
whose expression is highly restricted to DCs and which has
potent costimulatory properties for T cells. In particular,
B7-DC strongly costimulates IFN-g production much
more strongly than B7.1 while not costimulating IL-4 or
IL-10 production. These in vitro findings suggest that, in
addition to IL-12, B7-DC may be an important DC medi-
ator of Th1 responses. The human orthologue of B7-DC is
also expressed in monocyte-derived DCs, though confir-
mation of biological equivalence awaits functional studies
with human T cells. Mature monocyte-derived DCs in hu-
mans and CD8a1 DCs in mice induce very strong Th1 re-
sponses, whereas immature human DCs induce IL-10 pro-
duction and differentiation of regulatory T cells that inhibit
Th1 effector responses (34–36). The role of plasmacytoid
DCs in humans and murine CD8a2 DCs in mediating
Th2 responses remains unresolved (37, 38). It will be im-
portant to directly correlate B7-DC expression in these dif-
ferent DC subtypes with their ability to initiate Th1 effec-
tor responses.
The restricted expression of B7-DC contrasts with the
previously described B7 family members, suggesting that it
participates in different immune responses than the defined
B7.1/2 pathways. Although a weak B7-DC signal was de-
tected by RT-PCR in activated macrophages, preliminary
real-time RT-PCR analysis indicates that B7-DC mRNA
expression in DCs is .15-fold higher than in activated
macrophages (data not shown). Antibody staining likewise
detects very low levels of B7-DC on the surface of acti-
vated macrophages but it is unclear whether such low levels
could contribute significantly to T cell activation by mac-
rophages.
Although B7-DC fails to bind CD28 or CTLA-4, it
does bind PD-1, a receptor for B7-H1/PD-L1 (18, 39, 40).
The strong homology between B7-DC and B7-H1/PD-L1
(greater than that between B7.1 and B7.2), the close physi-
cal linkage between B7-DC and hB7-H1/PD-L1, and
their binding to a common receptor suggests that they are
related by a relatively recent duplication event. This is
highly analogous to B7.1 and B7.2, which both map to
within 1 megabase on mouse chromosome 16 and human
chromosome 3 (41). It will be important to discern the rel-
ative biologic roles of B7-DC versus B7-H1/PD-L1 as me-
diated by PD-1 and other putative receptor(s). PD-1 is ex-
pressed subsequent to T cell activation and appears to
inhibit T cell activation and induce apoptosis under condi-
tions of T cell stimulation with high concentrations of
anti-CD3. PD-1 knockout mice develop an autoimmune
syndrome (18) characterized by clinical manifestations of
hypertrophic cardiomyopathy. In contrast, Dong et al. (17)
found that B7-H1/PD-L1 costimulated T cell proliferation
and cytokine release at lower concentrations of anti-CD3.
Thus, by analogy to the situation with CD28 and CTLA-4,
PD-L1 may be a counterreceptor for an as yet unidentified
activating receptor. Despite sharing PD-1 as a binding part-
ner, B7-DC and B7-H1/PD-L1 appear to demonstrate dif-
ferences in lymphokine costimulation patterns. For exam-
ple, B7-H1/PD-L1 has been reported to costimulate IL-10
production by T cells whereas B7-DC does not. The mo-
lecular basis for these differences awaits the elucidation of
binding affinities as well as the complete receptor comple-
ment for these two costimulatory molecules.
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